首页> 外文期刊>Journal of cellular biochemistry. >Zellweger spectrum disorder patient–derived fibroblasts with the PEX1‐Gly843Asp allele recover peroxisome functions in response to flavonoids
【24h】

Zellweger spectrum disorder patient–derived fibroblasts with the PEX1‐Gly843Asp allele recover peroxisome functions in response to flavonoids

机译:Zellweger谱紊乱患者衍生的成纤维细胞与PEX1-GLY843ASP等位基因响应黄酮类化合物回收过氧缺体功能

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Zellweger spectrum disorder (ZSD) results from biallelic mutations in PEX genes required for peroxisome biogenesis. PEX1‐G843D is a common hypomorphic allele in the patient population that is associated with milder disease. In prior work using a PEX1‐G843D/null patient fibroblast line expressing a green fluorescent protein (GFP) reporter with a peroxisome‐targeting signal (GFP‐PTS1), we demonstrated that treatments with the chemical chaperone betaine and flavonoid acacetin diacetate recovered peroxisome functions. To identify more effective compounds for preclinical investigation, we evaluated 54 flavonoids using this cell‐based phenotype assay. Diosmetin showed the most promising combination of potency and efficacy (EC50 2.5?μM). All active 5′,7′‐dihydroxyflavones showed greater average efficacy than their corresponding flavonols, whereas the corresponding flavanones, isoflavones, and chalcones tested were inactive. Additional treatment with the proteostasis regulator bortezomib increased the percentage of import‐rescued cells over treatment with flavonoids alone. Cotreatments of diosmetin and betaine showed the most robust additive effects, as confirmed by three independent functional assays in primary PEX1‐G843D patient cells, but neither agent was active alone or in combination in patient cells homozygous for the PEX1 c.2097_2098insT null allele. Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1‐G843D patient cells, but none of these proteins increased in PEX1 null cells. We propose that diosmetin acts as a pharmacological chaperone that improves the stability, conformation, and functions of PEX1/PEX6 exportomer complexes required for peroxisome assembly. We suggest that diosmetin, in clinical use for chronic venous disease, and related flavonoids warrant further preclinical investigation for the treatment of PEX1‐G843D–associated ZSD.
机译:摘要Zellweger谱系障碍(ZSD)由异氧基酶体生物发生所需的PEX基因中的双腿突变结果。 PEX1-G843D是患者患者患者患者患者患有较高疾病的常见的低度等位基因。在现有的工作中,使用具有过氧化物靶向信号(GFP-PTS1)的绿色荧光蛋白(GFP)报告器的PEX1-G843D /零患者成纤维细胞线(GFP-PTS1),我们证明了用化学伴侣甜菜碱和黄酮类异丙酸糖苷酸的治疗回收过氧缺氧蛋白功能。为了确定更有效的临床前研究化合物,我们使用该细胞基表型测定评估了54种黄酮类化合物。 Diosmetin显示出最有希望的效力和功效组合(EC50 2.5?μm)。所有活性5',7'-二羟基氟胺显示出比​​其相应的黄酮醇更高的平均疗效,而相应的黄烷酮,异黄酮和测试的Chalces是无活性的。用蛋白质调节剂硼替佐米的额外处理增加了进口救出的细胞的百分比,单独使用黄酮类化合物治疗。 Diosmetin和Betaine的CoTreatments显示出最稳健的添加剂效应,如在初级Pex1-G843D患者细胞中的三个独立功能测定的确认,但既不是单独活性的,也不是患者纯合的患者细胞中的含有零型等位基因的患者细胞。此外,Diosmetin治疗在PEX1-G843D患者细胞中增加了PEX1,PEX6和PEX5蛋白水平,但是这些蛋白质中没有一个在PEX1零细胞中增加。我们提出Diosmetin作为药理伴侣,其提高了过氧化物组装所需的PEX1 / PEX6蛋酯配合物的稳定性,构象和功能。我们建议在慢性静脉疾病的临床用途中,相关黄酮类化合物进行进一步的临床前调查PEX1-G843D相关ZSD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号